| Similar Articles |
|---|
 |
The Motley Fool
June 10, 2004
Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.   |
The Motley Fool
May 5, 2004
Mike Cianciolo |
CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways. |
The Motley Fool
June 2, 2004
Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine? |
The Motley Fool
February 12, 2004
Dave Marino-Nachison |
CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January. |
The Motley Fool
February 2, 2005
Alyce Lomax |
CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny. |
The Motley Fool
April 9, 2007
Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note. |
The Motley Fool
April 5, 2004
Dave Marino-Nachison |
Finally, Eckerd Sells J.C. Penney's drugstore operation will be split between CVS and Jean Coutu. |
The Motley Fool
May 9, 2005
Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note. |
The Motley Fool
August 8, 2005
Mike Cianciolo |
A Cautiously Optimistic CVS The retail pharmacy nudges guidance up after an impressive quarter. All things considered, the outlook seems bright for investors in this company. |
The Motley Fool
June 11, 2007
Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note. |
The Motley Fool
January 8, 2007
Matthew Crews |
CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note. |
The Motley Fool
March 22, 2004
Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good. |
The Motley Fool
July 5, 2005
Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work. |
The Motley Fool
March 24, 2004
Dave Marino-Nachison |
Eking Out an Eckerd Deal Investors are still waiting for a new leader to be crowned in the U.S. drugstore business. |
The Motley Fool
September 27, 2007
Ryan Fuhrmann |
Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired. |
The Motley Fool
September 14, 2006
Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector. |
The Motley Fool
March 5, 2004
Dave Marino-Nachison |
Longs Coming Up Short Investors who bid on a Longs buyout haven't been rewarded in recent months. |
The Motley Fool
March 9, 2005
Steven Mallas |
CVS Comps Feast on Flu CVS enjoys a nice jump in same-store sales for the month of February -- thanks, in part, to colds and the flu. |
The Motley Fool
August 1, 2007
Ryan Fuhrmann |
Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one. |
The Motley Fool
August 15, 2005
Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors. |
The Motley Fool
June 25, 2004
Steven Mallas |
Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio? |
The Motley Fool
January 4, 2008
Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December. |
The Motley Fool
May 8, 2007
Ryan Fuhrmann |
CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results. |
The Motley Fool
August 4, 2004
Phil Wohl |
CVS's Prescription for Competition The national drugstore chain is looking to take advantage of increased size. |
BusinessWeek
September 19, 2005
Gene G. Marcial |
CVS' Ever-Expanding Aisles According to analysts, the aging population and improving pipeline of new drugs will help the retail pharmacy achieve its goal of 15% overall long-term earnings growth. Investors, take note. |
The Motley Fool
January 5, 2004
Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales. |
The Motley Fool
November 2, 2006
Ryan Fuhrmann |
CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note. |
The Motley Fool
July 6, 2004
Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them. |
The Motley Fool
July 6, 2004
Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%. |
The Motley Fool
December 8, 2004
Nathan Slaughter |
What's Wrong at Rite-Aid? Rite-Aid steers guidance lower after a difficult November. |
The Motley Fool
June 28, 2005
Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever. |
The Motley Fool
March 9, 2004
Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers. |
The Motley Fool
January 3, 2005
Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool
June 25, 2007
Ryan Fuhrmann |
Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see. |
The Motley Fool
August 3, 2004
Rich Duprey |
Penney Kicks Drugstore Habit The retailer has completed its sale of Eckerd Drugs to focus on selling clothes. While investors can and should enjoy Penney's current clear-eyed plans, they ought to keep a watchful eye out for any relapse. |
The Motley Fool
March 28, 2005
Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen? |
The Motley Fool
September 26, 2007
Ryan Fuhrmann |
Foolish Forecast: Does Rite Aid Have the Right Rx? The retail pharmacy is set to release it second-quarter financial results. Investors, here is what you can expect to see. |
The Motley Fool
December 23, 2003
Dave Marino-Nachison |
Duane Reade's NY Story The well-known New York drugstore chain is going private after just under six years. |
The Motley Fool
January 4, 2005
Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship. |
The Motley Fool
April 11, 2008
Ryan Fuhrmann |
Rite Aid Hasn't Fully Recovered Rite Aid needs to be nursed back to health after its acquisition of Brooks Eckerd. |
The Motley Fool
February 3, 2006
Nathan Parmelee |
CVS Looks Healthy The drugstore chain handles acquisitions without faltering -- this stock may be worth considering. |
The Motley Fool
January 13, 2004
Alyce Lomax |
CVS Fever Drug stores benefit from the flu bug, but for how much longer? |
The Motley Fool
October 6, 2004
Steven Mallas |
Walgreen Getting Greener The retail pharmacy's comps for September are once again healthy. Capital growth is the focus of the total return on this stock, making the dividend payout more of an indicator than a palpable engine of appreciation at this stage. |
The Motley Fool
August 17, 2004
Nathan Slaughter |
J.C. Penney on the Rise The retailer hits its stride after shedding Eckerd Drugstores. |
The Motley Fool
October 5, 2007
Timothy M. Otte |
CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition. |
The Motley Fool
September 22, 2006
Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note. |
The Motley Fool
August 3, 2007
Ryan Fuhrmann |
CVS Caremark Is No Sicko Pharmacy powerhouse CVS Caremark is looking to blaze a new health-care trail with the recent merger of their drugstore and pharmacy benefit management operations. |
The Motley Fool
May 21, 2004
Mike Cianciolo |
Waiting on Wet Seal The women's apparel retailer Wet Seal widens losses. |
The Motley Fool
February 4, 2008
Timothy M. Otte |
CVS Has Major Mo' Fourth-quarter results cap a stellar year for the drugstore retailer. |
The Motley Fool
January 26, 2004
Jason Matthews |
A Penney Saved Department store retailer J.C. Penney cuts jobs and restructures. |
